Germany’s parliament approved healthcare reforms that raise mandatory rebates on branded medicines from 7% to 15.5%, despite pharma and industry group pushback. Lawmakers also cleared additional measures including higher prescription co-pays and tighter insurance rules tied to married couples. The package is projected to cut statutory health insurance costs by about 16.3 billion euros next year, with potential for larger savings over time. Germany also avoided a variable discount structure that industry had opposed, according to reporting. For biopharma and biotech in Europe, the decision affects pricing expectations, revenue planning, and launch economics under an EU market that continues to tighten spending controls.